Inventor
SCHLEGEL MARK K
US36 patents
Patents
36 patentsUS11504391B1Nov 22, 2022
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC18 citations84
US11015201B2May 25, 2021
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10995336B2May 4, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations83
US11613751B2Mar 28, 2023
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations78
US11834661B2Dec 5, 2023
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11492623B2Nov 8, 2022
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations73
US11326166B1May 10, 2022
Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations72
US11149276B2Oct 19, 2021
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations72
US11926832B2Mar 12, 2024
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations71
US11597932B2Mar 7, 2023
Chirally-enriched double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC3 citations70
US11208660B1Dec 28, 2021
Coronavirus iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations70
US12584130B2Mar 24, 2026
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12275938B2Apr 15, 2025
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC0 citations62
US12247203B2Mar 11, 2025
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC0 citations62
US12173289B2Dec 24, 2024
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US11959081B2Apr 16, 2024
Transthyretin (TTR) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations62
US11725207B2Aug 15, 2023
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations62
US12553053B2Feb 17, 2026
Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations61
US12480125B2Nov 25, 2025
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations61
US12473550B2Nov 18, 2025
Coagulation factor V (F5) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations61
US12331297B2Jun 17, 2025
Coagulation factor V (F5) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations61
US11649459B2May 16, 2023
Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases
ALNYLAM PHARMACEUTICALS INC0 citations61
US12522822B2Jan 13, 2026
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations60
US11162103B2Nov 2, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations60
US12565653B2Mar 3, 2026
ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations59
US12404508B2Sep 2, 2025
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations59
US12391945B2Aug 19, 2025
Coronavirus IRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations59
US11993774B2May 28, 2024
Huntingtin (HTT) iRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations59
US11965166B2Apr 23, 2024
Complement factor B (CFB) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations59
US12365896B2Jul 22, 2025
Complement component C3 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations58
US12258565B2Mar 25, 2025
Complement component C3 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations58
US12049630B2Jul 30, 2024
Factor XII (F12) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations56
US12545914B2Feb 10, 2026
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations55
US12516322B2Jan 6, 2026
Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations53
US11866710B2Jan 9, 2024
Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations51
US12416006B2Sep 16, 2025
Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations43